Grifols (GIFLF) Other Working Capital Changes (2015 - 2025)
Grifols' (GIFLF) quarterly Other Working Capital Changes came in at $52.9 million in Q4 2016, down 30.42% on a YoY basis from $76.1 million in Q1 2016, and up 22.98% quarter-over-quarter from $43.0 million in Q3 2016.
Analysis
Grifols (GIFLF) Other Working Capital Changes (2015 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Other Working Capital Changes for 7 consecutive years, with $52.9 million the latest figure, recorded in Q4 2016.
- For the quarter ending Q4 2016, Other Working Capital Changes fell 30.42% year-over-year to $52.9 million; the trailing twelve-month figure through Dec 2016 stood at $259.3 million (down 13.7% YoY), and the FY2025 full-year result was $788.6 million, down 0.81% from the prior year.
- Other Working Capital Changes improved to $52.9 million in Q4 2016 per GIFLF's latest filing, from $43.0 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at -$36.1 million in Q4 2025 and bottomed at -$596.2 million in Q4 2022.
- Historically, Other Working Capital Changes has averaged -$340.9 million across 3 years, with a median of -$390.6 million in 2023.
- The sharpest annual moves came in 2012 and 2014: Other Working Capital Changes surged 2749.11% in 2012, then plunged 230.37% in 2014.
- Over 5 years, Other Working Capital Changes stood at $109.7 million in 2012, then sank by 43.15% to $62.4 million in 2013, then rose by 29.48% to $80.7 million in 2014, then retreated by 5.77% to $76.1 million in 2015, then slumped by 30.42% to $52.9 million in 2016.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered $52.9 million, $43.0 million, and $76.1 million for Q4 2016, Q3 2016, and Q4 2015 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -36.09 Mn |
| Dec 31, 2025 | -36.09 Mn |
| Dec 31, 2023 | -390.57 Mn |
| Dec 31, 2023 | -390.57 Mn |
| Dec 31, 2022 | -596.18 Mn |
| Dec 31, 2022 | -596.18 Mn |
| Dec 31, 2016 | 53.27 Mn |
| Dec 31, 2016 | 53.27 Mn |
| Sep 30, 2016 | -496.93 Mn |
| Sep 30, 2016 | -496.93 Mn |
| Dec 31, 2015 | -282.48 Mn |
| Dec 31, 2015 | -282.48 Mn |
| Sep 30, 2015 | 35.08 Mn |
| Sep 30, 2015 | 35.08 Mn |